Previous studies have demonstrated a significant MET overexpression in numerous tumor types including glioblastoma (4), melanoma (5), colorectal (6), breast (7), lung (8), gastric (9), thyroid (10) and prostate cancer (11). The gene discussed is MET; the disease is prostate carcinoma.